• 1
    The World Health Organization Statistical Information Service (WHOSIS) Global Burden of Disease Estimates 2002., accessed 12 December 2005.
  • 2
    Antithrombotic Trialists’ Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324: 71.
  • 3
    Goldstein RE, Andrews M, Hall WJ, Moss AJ for the Multicenter Myocardial Ischemia Research Group. Marked reduction in long-term cardiac deaths with aspirin after a coronary event. J Am Coll Cardiol 1996; 28: 326.
  • 4
    Pearson TA, Blair SN, Daniels SR, et al. AHA guidelines for primary prevention of cardiovascular disease and stroke: 2002 update: consensus panel guide to comprehensive risk reduction for adult patients without coronary or other atherosclerotic vascular diseases. American Heart Association Science Advisory and Coordinating Committee. Circulation 2002; 106: 388.
  • 5
    Hennekens CH, Dyken ML, Fuster V. Aspirin as a therapeutic agent in cardiovascular disease: a statement for healthcare professionals from the American Heart Association. Circulation. 1997; 96: 27513.
  • 6
    Centers for Disease Control and Prevention (CDC). Prevalence of aspirin use to prevent heart disease — Wisconsin, 1991, and Michigan, 1994. MMWR Morb Mortal Wkly Rep 1997; 46: 498502.
  • 7
    Derry S, Loke YK. Risk of gastrointestinal haemorrhage with long term use of aspirin: meta-analysis. BMJ 2000; 321: 1183.
  • 8
    Weisman SM, Graham, DY. Evaluation of the benefits and risks of low-dose aspirin in the secondary prevention of cardiovascular and cerebrovascular events. Arch Intern Med 2002; 162: 2197.
  • 9
    Kahaleh M, Vinciane M, Mulkay J-P, Arvanitaki M, Buset M. Preoperative esophagogastroduodenoscopy in patients undergoing cardiac surgery. Gastroenterology 2001; 120: A233.
  • 10
    Yeomans ND, Lanas AI, Talley NJ, et al. Prevalence and incidence of gastroduodenal ulcers during treatment with vascular protective doses of aspirin. Aliment Pharmacol Ther 2005; 22: 795801.
  • 11
    Fries JF, Williams CA, Bloch DA, Michel BA. Nonsteroidal anti-inflammatory drug-associated gastropathy: incidence and risk factor models. Am J Med 1991; 91: 21322.
  • 12
    Griffin MR. Epidemiology of nonsteroidal anti-inflammatory drug-associated gastrointestinal injury. Am J Med 1998; 104: 23S9S.
  • 13
    Rockall TA, Logan RFA, Devlin HB, Northfield TC. Incidence of and mortality from acute upper gastrointestinal hemorrhage in the UK. BMJ 1995; 311: 22226.
  • 14
    Katschinski BD, Logan RFA, Davies J, Langman MJS. Audit of mortality in upper gastrointestinal bleeding. Postgraduate Medical Journal 1989; 65: 9137.
  • 15
    Rockall TA, Logan RFA, Devlin HB, Northfield TC. Risk assessment after acute upper gastrointestinal hemorrhage. Gut 1996; 38: 31621.
  • 16
    Lanas A, Perez-Aisa MA, Feu F, et al. Investigators of the Asociacion Espanola de Gastroenterologia (AEG). A nationwide study of mortality associated with hospital admission due to severe gastrointestinal events and those associated with nonsteroidal antiinflammatory drug use. Am J Gastroenterol 2005; 100: 168593.
    Direct Link:
  • 17
    Lai KC, Lam SK, Chu KM, et al. Lansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin use. N Engl J Med 2002; 346: 20338.
  • 18
    Chan FK, Ching JY, Hung LC, et al. Clopidogrel vs. aspirin and esomeprazole to prevent recurrent ulcer bleeding. N Engl J Med 2005; 352: 23844.
  • 19
    Ibanez L, Vidal X, Vendrell L, Moretti U, Laporte JR. Upper gastrointestinal bleeding associated with antiplatelet drugs. Aliment Pharmacol Ther 2006; 23: 23542.
  • 20
    Cryer B, Feldman M. Effects of very low dose daily, long-term aspirin therapy on gastric, duodenal, and rectal prostaglandin levels and on mucosal injury in healthy humans. Gastroenterology 1999; 117: 1725.
  • 21
    Abraham HS, El-Serag HB, Johnson ML. National adherence to evidence-based guidelines for the prescription of nonsteroidal anti-inflammatory drugs. Gastroenterology 2005; 129: 11718.
  • 22
    Sturkenboom MC, Burke TA, Dieleman JP, et al. Underutilization of preventive strategies in patients receiving NSAIDs. Rheumatology (Oxford) 2003; 42 (Suppl. 3): iii2331.
  • 23
    Harrington RA, Becker RC, Ezekowitz M, et al. Antithrombotic therapy for coronary artery disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126: 513S.
  • 24
    Lanas A, Sekar MC, Hirschowitz BI. Objective evidence of aspirin use in both ulcer and nonulcer upper and lower gastrointestinal bleeding. Gastroenterology 1992; 103: 8629.
  • 25
    Recommendations for the medical management of osteoarthritis of the hip and knee. 2000 update. American College of Rheumatology Subcommittee on Osteoarthritis Guidelines. Arthritis Rheum 2000; 43: 190515.
  • 26
    Lanza FL. A guideline for the treatment and prevention of NSAID induced ulcers. Members of the Ad Hoc Committee on Practice Parameters of the American College of Gastroenterology. Am J Gastroenterol 1998; 93: 203746.
    Direct Link:
  • 27
    Robinson MG, Griffin JW Jr, Bowers J, et al. Effect of ranitidine on gastroduodenal mucosal damage induced by nonsteroidal antiinflammatory drugs. Dig Dis Sci 1989; 34: 4248.
  • 28
    Ehsanullah RS, Page MC, Tildesley G, Wood JR. Prevention of gastroduodenal damage induced by non-steroidal anti-inflammatory drugs: controlled trial of ranitidine. BMJ 1988; 297: 101721.
  • 29
    Graham DY, Agrawal NM, Roth SH. Prevention of NSAID-induced gastric ulcer with misoprostol: multicentre, double-blind, placebo-controlled trial. Lancet 1988; 2: 127780.
  • 30
    Hawkey CJ, Karrasch JA, Szczepanski L, et al. Omeprazole compared with misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs. Omeprazole vs. Misoprostol for NSAID-induced Ulcer Management (OMNIUM) Study Group. N Engl J Med 1998; 338: 72734.